BidaskClub lowered shares of Tigenix (NASDAQ:TIG) from a sell rating to a strong sell rating in a research report sent to investors on Saturday morning.

TIG has been the subject of a number of other reports. Canaccord Genuity reaffirmed a buy rating and issued a $30.00 price objective on shares of Tigenix in a research note on Tuesday, October 31st. Zacks Investment Research cut Tigenix from a hold rating to a sell rating in a research note on Saturday, October 21st. Two investment analysts have rated the stock with a sell rating and three have given a buy rating to the company. The company currently has an average rating of Hold and a consensus price target of $24.50.

Shares of Tigenix (NASDAQ TIG) opened at $23.27 on Friday. Tigenix has a 1 year low of $10.77 and a 1 year high of $25.72. The company has a debt-to-equity ratio of 0.10, a current ratio of 1.37 and a quick ratio of 1.36.

An institutional investor recently bought a new position in Tigenix stock. EAM Investors LLC bought a new position in shares of Tigenix NV (NASDAQ:TIG) in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund bought 155,886 shares of the company’s stock, valued at approximately $3,517,000. EAM Investors LLC owned approximately 1.20% of Tigenix at the end of the most recent reporting period. Institutional investors and hedge funds own 5.31% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This story was first published by Watch List News and is the property of of Watch List News. If you are accessing this story on another publication, it was stolen and reposted in violation of international copyright & trademark laws. The correct version of this story can be viewed at

Tigenix Company Profile

TiGenix NV, a biopharmaceutical company, develops and commercializes therapeutics from its proprietary technology platforms of allogeneic or donor derived stem cells. Its stem cell programs are based on proprietary validated platforms of allogeneic expanded stem cells targeting autoimmune, inflammatory, and heart diseases.

Receive News & Ratings for Tigenix NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tigenix NV and related companies with's FREE daily email newsletter.